Vamvouris Theodora, Hadi Suhail
Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029-6574, USA.
Rev Recent Clin Trials. 2006 Sep;1(3):201-5. doi: 10.2174/157488706778250122.
Patients afflicted with moderate to severe psoriasis experience a reduction in the quality of life. They not only suffer the aggravation associated with the pain, itchiness, and bleeding of the psoriatic lesions, but also experience a negative impact on their daily functions and social well-being. Unfortunately, traditional therapeutic measures have not been effective enough in treating individuals suffering from moderate to severe forms of psoriasis. Most of the conventional medications have produced at best only partial responses. However, the recent chimeric monoclonal TNF-alpha inhibiting antibody, infliximab, has been proven effective for the treatment of patients with moderate to severe psoriasis. Most patients treated with infliximab have shown rapid and remarkable improvement in the clinical manifestations of the disease. This article will closely examine the efficacy and safety of infliximab through the analysis of past case reports and clinical trials.
患有中度至重度银屑病的患者生活质量会下降。他们不仅遭受银屑病皮损疼痛、瘙痒和出血带来的不适，而且日常功能和社会福祉也会受到负面影响。不幸的是，传统治疗措施在治疗中度至重度银屑病患者方面效果不够显著。大多数传统药物最多只能产生部分疗效。然而，最近的嵌合单克隆肿瘤坏死因子-α抑制抗体英夫利昔单抗已被证明对治疗中度至重度银屑病患者有效。大多数接受英夫利昔单抗治疗的患者在疾病临床表现上都有快速且显著的改善。本文将通过分析过去的病例报告和临床试验来仔细研究英夫利昔单抗的疗效和安全性。
